Jeremy Grantham Incyte Corp Transaction History

Grantham, Mayo, Van Otterloo & Co. LLC

$33.7 Billion
Q3 2025

A detailed history of Jeremy Grantham (Grantham, Mayo, Van Otterloo & Co. LLC) transactions in Incyte Corp stock. As of the latest transaction made, Grantham, Mayo, Van Otterloo & Co. LLC holds 248,843 shares of INCY stock, worth $25.9 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

248,843

Previous 305,638 18.58%

Holding current value

$25.9 Million

Previous $20.8 Million 1.4%

% of portfolio

0.06%

Previous 0.07%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$67.27 - $86.96 $3.82 Million - $4.94 Million	-56,795 Reduced 18.58%	248,843 $21.1 Million
Q2 2025 Aug 13, 2025	SELL	$55.17 - $71.22 $5.68 Million - $7.34 Million	-103,044 Reduced 25.21%	305,638 $20.8 Million
Q1 2025 May 14, 2025	SELL	$60.0 - $75.26 $2.82 Million - $3.54 Million	-47,017 Reduced 10.32%	408,682 $24.7 Million
Q4 2024 Feb 13, 2025	SELL	$65.08 - $83.38 $8.16 Million - $10.5 Million	-125,360 Reduced 21.57%	455,699 $31.5 Million
Q3 2024 Nov 13, 2024	SELL	$57.33 - $68.61 $266,756 - $319,242	-4,653 Reduced 0.79%	581,059 $38.4 Million

Q2 2024 Aug 13, 2024	BUY	$51.18 - $63.75 $3.12 Million - $3.88 Million	60,865 Added 11.6%	585,712 $35.5 Million
Q1 2024 May 14, 2024	SELL	$56.55 - $66.59 $864,819 - $1.02 Million	-15,293 Reduced 2.83%	524,847 $29.9 Million
Q4 2023 Feb 13, 2024	BUY	$52.16 - $64.19 $1.76 Million - $2.17 Million	33,828 Added 6.68%	540,140 $33.9 Million
Q3 2023 Nov 13, 2023	BUY	$57.77 - $65.93 $4.95 Million - $5.65 Million	85,702 Added 20.38%	506,312 $29.2 Million
Q2 2023 Aug 14, 2023	SELL	$60.95 - $75.51 $480,895 - $595,773	-7,890 Reduced 1.84%	420,610 $26.2 Million
Q1 2023 May 12, 2023	SELL	$70.23 - $86.01 $105,345 - $129,015	-1,500 Reduced 0.35%	428,500 $31 Million
Q4 2022 Feb 13, 2023	BUY	$67.18 - $84.11 $3.8 Million - $4.75 Million	56,500 Added 15.13%	430,000 $34.5 Million
Q3 2022 Nov 10, 2022	SELL	$66.18 - $82.86 $701,508 - $878,316	-10,600 Reduced 2.76%	373,500 $24.9 Million
Q2 2022 Aug 12, 2022	BUY	$66.18 - $83.18 $99,270 - $124,770	1,500 Added 0.39%	384,100 $29.2 Million
Q1 2022 May 13, 2022	BUY	$66.02 - $79.71 $4.13 Million - $4.99 Million	62,600 Added 19.56%	382,600 $30.4 Million
Q4 2021 Feb 11, 2022	BUY	$63.34 - $74.11 $14 Million - $16.4 Million	221,300 Added 224.21%	320,000 $23.5 Million
Q3 2021 Nov 12, 2021	BUY	$68.67 - $84.02 $6.78 Million - $8.29 Million	98,700 New	98,700 $6.79 Million

Others Institutions Holding INCY

# of Institutions

797

Shares Held

205M

Call Options Held

638K

Put Options Held

635K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $23.2B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track Jeremy Grantham's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.

Account